NxThera developed its Convective Water Vapor Energy (WAVE) technology platform to treat a variety of endourological conditions beginning with BPH. NxThera's FDA cleared Rezūm System to treat BPH uses radiofrequency energy to create sterile water vapor, or steam, to convectively deliver targeted, precise thermal energy treatments in a simple procedure with minimal discomfort, and provide improvements in LUTS symptoms, urine flow and quality of life. The Company is furthering the application of the technology platform through advanced research and development targeting the treatment of prostate cancer and kidney cancer.
NxThera has filed 23 patents.
Mammal male reproductive system, Penis, Prostate cancer, Andrology, Inflammations
Mammal male reproductive system, Penis, Prostate cancer, Andrology, Inflammations
Latest NxThera News
Sep 21, 2023
| Unveiled by FMI The global cold disposable biopsy forceps market is poised to experience remarkable growth, with a projected valuation of approximately US$ 634.6 Million by 2023. This upward trend is expected to continue, with the market expanding at a compound annual growth rate (CAGR) of 8.2%, culminating in a valuation of around US$ 1.40 Billion by 2033, according to a recent study conducted by Future Market Insights. Notably, oval cups, a product segment within the market, currently hold a dominant position, accounting for nearly 46.0% of the total market share in 2023. The cold disposable biopsy forceps market will register high demand due to the rising prevalence of bronchitis and gastrointestinal disorders such as IBD and GERD among the geriatric population and the increasing awareness of endoscopic procedures. There is also a rise in the adoption of disposable biopsy forceps that are reliable for test sampling expect to gain popularity. Click Here to Access Your Visuals-Packed Report! At present, the minimally invasive technology, with the endoscope system at the core, has been extended to obstetrics, general surgery, otolaryngology, gynecology, thoracic surgery, urology, pediatrics, and other departments. Minimally-invasive endoscopic technology has become an indispensable technology for the diagnosis and treatment of chronic diseases associated with breathing, digestion, urology, otolaryngology, and so on. With the rising demand for endoscopic minimally invasive technology and continuous improvement in endoscopic processing technology, endoscopic applications have become prominent in almost all departments. The growing demand for diagnosis and endoscopic treatment is expected to further boost the demand for cold disposable biopsy forceps. Numerous recent technological advances are becoming available to endoscopists. An abundance of new imaging modalities is expected to facilitate early detection of chronic disorders and other pathological entities. Most of these techniques remain investigational and are currently in clinical trials to determine patient benefits. Companies are expanding their product lines by manufacturing different types of products for a wide range of applications. For instance, Micro-Tech Endoscopy is mainly engaged in the R&D, manufacturing, and sales of minimally invasive medical devices, in line with its mission of supporting clinicians with technology and innovation. Key Takeaways from Cold Disposable Biopsy Forceps Market Study Oval cup forceps gained popularity and their sales are expected to grow at a CAGR of 8.8% during the forecast period. 8 mm diameter have sharpened cups whch ensure superior cutting performance and lead to fewer artefacts and less bleeding. The segment is therefore expected to account for a share of 24.9% in 2021. 2300 mm length forceps has precise jaws, no tearing and cause small wound. The segment accounted for the highest share of 37.9% in 2021. Upper GI Endoscopy dominated the application segment with the highest market share of 24.9% in 2021. Hospitals accounted for the largest share of around 42.0% in 2021 and will remain the end user in the market. Click Here to Request Methodology! Who is winning? The key players are focusing on acquisitions and partnerships with small players and suppliers to increase their market presence. Besides this, they are adopting various strategies to expand their footprint. For instance: iIn April 2018, Boston Scientific Corporation closed its acquisition of NxThera. The company developed a minimally-invasive therapy the Rezūm system, for patients suffering from symptomatic benign prostatic hyperplasia. With the completion of the acquisition, NxThera became a part of Boston Scientific’s urology and pelvic health business. Moreover, the manufacturers are focusing on research and development activities for developing cold disposable biopsy forceps for various research applications. In july 2020, ChargePoint and STERIS collaborated to develop a fully validated sterile transfer solution to offer a unique and integrated solution for sterile product transfer. Some of the leading players in the cold disposable biopsy forceps market include but are not limited to Olympus Corporation, Boston Scientific Corporation, STERIS, CONMED Corporation, Cook Medical, Micro-Tech Endoscopy, Anrei Medical and other companies. Key Market Segments Covered in Cold Disposable Biopsy Forceps Industry Research By Product:
NxThera Frequently Asked Questions (FAQ)
When was NxThera founded?
NxThera was founded in 2008.
Where is NxThera's headquarters?
NxThera's headquarters is located at 7351 Kirkwood Lane N, Maple Grove.
What is NxThera's latest funding round?
NxThera's latest funding round is Acquired.
How much did NxThera raise?
NxThera raised a total of $122.9M.
Who are the investors of NxThera?
Investors of NxThera include Boston Scientific, Aberdare Ventures, Arboretum Ventures, Apple Tree Partners, Ally Bridge Group and 13 more.
Who are NxThera's competitors?
Competitors of NxThera include MicroTransponder, Ecochlor, Vertiflex, Articulinx, Advanced Biosurfaces and 12 more.
Compare NxThera to Competitors
Articulinx, Inc is developing minimally invasive implants for the treatment of osteo-arthritis.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.
Researcher and developer of a minimally invasive, encapsulated cellular transplant device for the treatment of diabetes. The company sold its assets to Novocell.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.
Southern Implants was established in 2006 to commercialize in North America, South America and Asia, dental implant technologies that have been sold in Europe and other parts of the world for over two decades. Southern Implants, with headquarters in Irvine, California, provides implant surgeons and restorative dentists with a broad range of implants and restorative components that work seamlessly with existing systems while offering unique, innovative features that simplify even the most complex clinical challenges. Southern Implants' proprietary products, the MAX and Co-Axis implant systems provide unique therapies which will enable the merged company to differentiate itself competitively and to grow within this large and expanding market. In addition, Southern Implants manufactures a complete line of generic implants. The MAX Implant is an FDA-cleared implant for immediate placement and immediate load in a molar extraction socket. The Co-Axis Implant is the only implant on the market with 12° and 24° angle incorporated into the implant for multiple applications.